Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Competition watchdog to probe HRT medication rights sale

The CMA has announced the launch of a merger inquiry into manufacturer Viatris’s sale of “certain rights” to two of its HRT drugs to Theramex.

The Competition and Markets Authority (CMA) will probe manufacturer Theramex’s purchase of “certain rights” to Femoston and Duphaston, two of Viatris’s hormone replacement therapy (HRT) drugs, it announced today (February 6).

The competition watchdog said that has today launched a merger inquiry to investigate the purchase to determine whether it would lead to a “substantial lessening of competition” in the UK.

Read more: CMA launches first phase inquiry into Pharmacy2U/LloydsDirect merger

In October, Theramex announced that it had reached an agreement with Viatris to buy the European rights to the two HRT treatments. 

At the time, Theramex said that Viatris would retain the rights for Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) in Japan and Australia.

Read more: Hydrocortisone manufacturers face record £130m fine as appeal rejected

Then in December, Theramex announced that it had completed the purchase of the European rights to the two drugs, excluding the UK.

It said that its acquisition of Viatris’s UK rights to the products was “subject to regulatory approval”.

The CMA has invited comments on the purchase with a deadline of February 19.

Read more: ‘Abused dominant position': Appeal sees liothyronine manufacturer fined £41m

The deadline for the authority’s phrase one merger inquiry decision is April 4. 

C+D approached Theramex and Viatris for comment.

This is a breaking news story. More to follow…

Related Content

Topics

         
Foundation Training Pharmacist - Pre-Registration
Greater Manchester
£24,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD137938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel